MOTION EQUITY PARTNERS takes majority stake in POLARIS
Context
Motion Equity Partners has acquired a majority stake in Polaris, a leading manufacturer of omega-3 concentrates, from Demea Agro, which had invested in the company three years ago. This transaction is part of a broader strategy to drive external growth and international expansion, with ambitious plans to establish a US-based industrial site and double in size within the next five years. Historical shareholders of Polaris, including Cerea Partners, Seventure, and Picama, are reinvesting alongside Motion Equity Partners, which brings its expertise in supporting industrial companies in their international development. This deal enables Demea Agro to achieve a 3.5x return on its initial investment, with an internal rate of return (IRR) of 50%. The acquisition also strengthens Motion Equity Partners' portfolio of investments in high-growth industrial businesses. Legal and financial advisory services were provided by GCA, Eight Advisory, Forvis Mazars, Goodwin, and BDO.
POLARIS, which reported an EBITDA margin of in 2025, is valued in this transaction at an EV/EBITDA multiple of , a level to compare with the average currently observed in the Healthcare & Pharma sector (15.3x).
-> Deep-dive in Healthcare & Pharma market trends
Target
Polaris, established in 1994, is a specialized company that produces high-quality microalgae-based omega-3 concentrates for the dietary supplement, infant nutrition, and cosmetics industries. This Brittany-based enterprise has developed a unique expertise in lipid chemistry, enabling the transformation of crude oils into premium concentrates using proprietary technologies such as QualitySilver and GreenSilver. These complex processes ensure unparalleled product quality, combining high concentration, superior organoleptic properties, and resistance to oxidation. With a significant international presence, accounting for two-thirds of its revenue, Polaris holds a strategic position in a resilient and dynamic market.
Ent. Value
Equity Value
Multiples
EV / Revenue
EV / EBITDA
EV / EBIT
Historical Financials (EUR)
Similar deals in Life Sciences
| Date | Acquirer | Target | Country | Sector |
|---|---|---|---|---|
| 07/2026 | YOTTA CAPITAL / OUEST CROISSANCE | Les Laboratoires Herbolistique | FRANCE | Nutrition & Dietary Supplements |
| 07/2026 | BAIN CAPITAL | Vitabiotics | UNITED KINGDOM | Nutrition & Dietary Supplements |
| 06/2026 | BRIDGEPOINT | OBAGI MEDICAL | UNITED STATES | Generics / Labs |
| 06/2026 | CORDENPHARMA | AMBIOPHARM | UNITED STATES | CDMO |
| 06/2026 | COLUMBUS VENTURE PARTNERS / MERIEUX EQUITY PARTNERS | ONA THERAPEUTICS | SPAIN | R&D Biotech |
| 06/2026 | 3I | LABORATOIRE NUTERGIA | FRANCE | Nutrition & Dietary Supplements |
| 06/2026 | DHCARE | OTTOBOCK HUMAN MOBILITY | GERMANY | Medical Devices |
| 06/2026 | ABBVIE | APOGEE THERAPEUTICS | UNITED STATES | R&D Biotech |
| 05/2026 | STRYKER | AMPLITUDE VASCULAR SYSTEMS | UNITED STATES | Medical Devices |
| 04/2026 | Gilead Sciences | Arcellx | UNITED STATES | R&D Biotech |
REFERENCES
Revenue range: 50M - 100M EUR
Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of POLARIS by MOTION EQUITY PARTNERS are reserved for mynth community members. Register for free to unlock full data.
Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.
Press release: view release
Target: polaris
Acquirer: motion equity partners